CHNA

Fund Description
The Loncar China BioPharma ETF trades on Nasdaq under the symbol CHNA. It is made of up a basket of companies that are leading China s biotech revolution. With a focus on innovators, the fund contains globally listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that have a strategic role in growing China s drug industry. CHNA ETF offers this global exposure all in the convenience of one security that trades in the United States. It tracks the LCHINA index.
Fund Profile
Fund Name Loncar China Biopharma ETF
Fund Exchange Ticker CHNA
Fund Sponsor Exchange Traded Concepts
Fund ISIN US26922A3703
Net Expense Ratio 0.79 %
Fund Inception Date 14 August 2018
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Global or ExUS Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Loncar China BioPharma Index
Index Provider Loncar Investments
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Emerging Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent Asia
Key Statistics
Return As of Date 17 January 2019
Asset Under Management 2.02 Million (USD)
1 Month Total Return 2.29 %
Year To Date Return 7.13 %
1 Year Total Return
3 Year Annualized Total Return
NAV 20.1986
Share Outstanding 100,000
Top 10 Holdings (17 January 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
SINOPHARM GROUP CO-H 1099 EQUI 0.0571000000
AUSTAR LIFESCIENCE 6118 EQUI 0.0504000000
ZAI LAB LTD-ADR ZLAB EQUI 0.0498000000
BEIGENE LTD-ADR BGNE EQUI 0.0495000000
WUXI BIOLOGICS (CA 2269 EQUI 0.0473000000
SIHUAN PHARMACEUTICAL HLDGS 460 EQUI 0.0436000000
GUANGZHOU BAIYUNSHAN PHARM-H 874 EQUI 0.0421000000
CHINA RES PHARM GR 3320 EQUI 0.0411000000
SSY GROUP LTD 2005 EQUI 0.0397000000
SHANGHAI FOSUN PHARMACEUTI-H 2196 EQUI 0.0395000000